Table 2.
Sample name | Shannon | Simpson | ACE | Chao | Coverage |
---|---|---|---|---|---|
LC50_1 | 1.88 | 0.33 | 79.75 | 79.67 | 0.99 |
LC50_2 | 1.21 | 0.49 | 72.69 | 73.13 | 0.99 |
LC50_3 | 0.9 | 0.63 | 79.21 | 76.00 | 0.99 |
LC20_1 | 1.24 | 0.58 | 84.19 | 84.67 | 0.99 |
LC20_2 | 1.80 | 0.37 | 102.36 | 105.43 | 0.99 |
LC20_3 | 0.11 | 0.97 | 52.67 | 52.00 | 0.99 |
CK_1 | 2.97 | 0.15 | 91.81 | 91.14 | 0.99 |
CK_2 | 3.52 | 0.05 | 105.13 | 104.37 | 0.99 |
CK_3 | 2.65 | 0.16 | 89.18 | 90.00 | 0.99 |
CK: control group; LC20: treatment group with 0.0297 mg/mL of CAR; LC50: treatment group with 1.120 mg/mL of CAR. The numbers 1–3 following the sample names represent different replicates, respectively.